Wacker Biotech has completed the acquisition of Synco Bio Partners, with the objective of expanding its portfolio and further increasing its presence in the biopharmaceuticals market.

The acquisition was made from SynCo Bio Luxembourg.

Based in the Netherlands, the acquirer company is a contract manufacturer of biopharmaceutical proteins based on microbial systems, and a subsidiary of Wacker Chemie.

The target company, based in Luxembourg, has two fermentation lines with capacities of 1,500l and 270l respectively.

Unigreg has become a wholly owned subsidiary of UK-based pharmaceutical company Pacific Glory Development, with the latter having purchased the remaining 60% interest in the former from Alliance Pharmaceuticals.

The selling company is a subsidiary of Alliance Pharma.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The latest acquisition has been made for a consideration of £2.9m ($4.14m), which included £2.4m ($3.43m) in cash as initial payment and the remaining £0.5m ($0.71m) payable by 16 April 2019.

The outstanding shareholder loans of the group to Unigreg will be paid back in full before completion of the acquisition.

Alliance Pharmaceuticals appointed Numis Securities and Investec Bank as financial advisers for the transaction.

US-based biotechnology company Proteintech Group has agreed to acquire Humanzyme with the aim of further strengthening its position in the production of antibodies, proteins and ELISA kits.

“Swedish life science investment company Karolinska Development has divested its share in BioArctic for Skr12m ($1.43m).”

Based in the US, the target company is a provider of recombinant human proteins from human cells.

French biotech company Deinove has agreed to acquire Biovertis along with its subsidiary Morphochem for €0.9m ($1.11m) in shares.

Deinove will also acquire MCB3837 antibiotic compound programme of Morphochem and entire capital of Biovertis.

The acquisition will be made specifically from investment funds managed by TVM Capital.

Swedish life science investment company Karolinska Development has divested its share in BioArctic for Skr12m ($1.43m).

Karolinska Development has sold more than half a million shares of BioArctic resulting in full divestment. The company already sold its share worth Skr35m ($4.13m) earlier in November 2017.

Chinese pharmaceutical company Henan Lingrui Pharmaceutical is set to increase its stake in a biological pharmaceutical company to 90.5%.

The acquirer company has reached an agreement to purchase an additional 33.33% stake in the target company for CNY66.7m ($10.61m).

Czech Republic-based private equity firm Advent International and Sanofi are negotiating for the former to acquire the latter’s European generics business Zentiva.

The purchase consideration for the transaction is expected to be approximately €1.91bn ($2.37bn).

Advent International will work in collaboration with Sanofi to form a new independent operation following the acquisition.

Zentiva intends to utilise the proceeds to invest in operations, production facilities and R&D pipeline.